TIPT earnings analysis
What we found in TIPT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tiptree's Q2 reported earnings were dominated by the Fortegra sale: diluted EPS increased to $10.30 from $0.39, including a $372.2 million after-tax disposal gain. The remaining continuing business generated no revenue and a $6.4 million net loss, though lower expenses and higher Treasury interest income improved the pre-tax loss to $5.1 million from $12.5 million. The sales transformed liquidity, lifting cash and equivalents to $946.9 million, but also created a $204.8 million current tax payable expected largely before September 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Fortegra disposal drove $10.30 EPS
- Diluted EPS rose to $10.30 from $0.39 in Q2 2025, driven primarily by a $372.2 million after-tax gain on the May 29 Fortegra sale; discontinued operations contributed $395.7 million of net income.
- Corporate loss narrowed on lower costs
- Continuing-operations pre-tax loss narrowed by $7.3 million year over year to $5.1 million, as quarterly expenses fell 24.3% to $9.1 million and other income increased to $3.9 million from $0.9 million.
- Disposals substantially increased liquidity
- Cash and cash equivalents rose $916.1 million from year-end to $946.9 million, while marketable securities increased from $21.7 million to $158.2 million following the Fortegra and Reliance dispositions.
- Book value increased sharply
- Stockholders' equity increased to $907.1 million at June 30, 2026 from $752.4 million at December 31, 2025; book value per share reached $24.34, up 82.6% from $13.33 a year earlier.
- Capital returns continued
- The company repurchased 304,070 shares in June at an average $17.50 per share; $14.7 million remained under the $20.0 million repurchase authorization.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing business remains loss-making
- The reported $10.30 diluted EPS was largely nonrecurring: continuing operations recorded a $6.4 million net loss, while discontinued operations supplied $395.7 million of net income, including the $372.2 million Fortegra-sale gain.
- Revenue base was sold and is now absent
- Following the sales of Fortegra and Reliance, continuing-operations revenue was $0.0 million in Q2 2026, down from $0.1 million a year earlier; Fortegra and Reliance produced only $341.6 million and $5.5 million, respectively, before their sales during the quarter.
- Large near-term sale-related tax payment
- A $204.8 million current tax payable was established in connection with the Fortegra sale, and management expects the majority to be paid before September 30, 2026.
- Continuing operations consumed cash
- Cash used in continuing operating activities increased to $18.4 million for the first six months of 2026 from $13.7 million in the prior-year period; capex was not separately disclosed, so free cash flow cannot be calculated from the filing.
- No formal risk-factor update despite reshaping
- Item 1A states there were no material changes to risk factors from the 2025 10-K; however, total assets declined from $6.84 billion to $1.13 billion after the divestitures, materially changing the operating asset base.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $10.3
- Segment
- Continuing operations revenue: $0.0 million in Q2 2026, versus $0.1 million in Q2 2025.
- Segment
- Fortegra (discontinued): $341.6 million of Q2 2026 revenue, versus $513.0 million in Q2 2025.
- Segment
- Reliance (discontinued): $5.5 million of Q2 2026 revenue, versus $16.2 million in Q2 2025.
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS guidance. Management stated that $946.9 million of cash and equivalents, $158.2 million of marketable securities, and operating cash flow are expected to provide sufficient capital for general corporate needs over the next several years.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 30, 2026
- Tiptree Inc. reported $0 in revenue for Q1 2026, a significant decline from $0.4 million in Q1 2025. The company managed to post diluted EPS of $0.34, an increase from $0.13 in the previous year, led by strong…
- 10-K · March 9, 2026
- Tiptree’s 2025 10-K centers on the announced sales of its two largest operating businesses — Fortegra (insurance) and Reliance (mortgage) — which are now classified as held for sale and discontinued operations. The…
- 10-Q · October 31, 2025
- Tiptree reported Q3 revenue of $540,302,000 (Q3 2025) versus $494,362,000 in Q3 2024, driven by higher earned premiums and sizable net realized/unrealized gains. Operating margin compressed to 9.1% from 12.0% in the…
- 10-K · March 3, 2025
- Tiptree positions itself as a capital allocator focused on insurance (Fortegra) and credit-related businesses, emphasizing long-term, owner-oriented capital deployment and disciplined underwriting. Fortegra reported…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TIPT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever